Alexion Pharma recalls
certain lots of intravenous drug Soliris
Send a link to a friend
[June 02, 2014]
(Reuters)
- Alexion Pharmaceuticals
Inc said it is voluntarily recalling certain lots of
Soliris, an intravenous drug for two potentially fatal
blood disorders that can damage the kidneys, heart and
brain.
|
The company said the recall was related to its earlier manufacturing
process, which had prompted a similar recall in November.
Alexion initiated the recall due to the presence of visible
particles found in a single lot of Soliris during a test, the
company said in a statement.
The company said it did not expect the recall to have any financial
impact or interrupt supply of the drug.
(Reporting by Sruthi Ramakrishnan in Bangalore, Editing by Simon
Jennings)
![](http://archives.lincolndailynews.com/2014/Jun/02/images/ads/current/business_directory_filler.png)
[to top of second column] |
![](../images/ads/current/Symphony_122313.png)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |